Methotrexate Safety Tips (7.31.2026) Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow. And if you're ready to test your knowledge, take this week's RheumIQ quiz! https://t.co/3iE9ZAH7q4 https://t.co/y3ir6j6XIP

JAMA Review of Hip Fracture The July 16th edition of JAMA reviews the highly prevalent problem of hip fractures - a major global health burden: 14.2 million occur worldwide annually (280,000 in the US), with global incidence higher in women (833.9/100,000) than men https://t.co/TiiCjoq2Hj

New, Advanced Therapies in Gout New, Advanced Therapies in Gout explores the rapidly evolving therapeutic landscape beyond conventional urate-lowering therapy. https://t.co/0uNK0nOEp6 https://t.co/YD7tQu2QrT

U Alberta Rheumatology study of GCAPS score in 62 new onset, suspected GCA referrals. GCA Dx in 39 pts excluded in 23. 50% had a High risk GCAPS (screening) score, 38% Intermediate & 13% had Low risk GCAPs. Intermediate or High risk GCAPS sensitivity 97%, specificity 30%, PPV 70% https://t.co/HxHL60VAuO

In a Cohort of 410 #SLE pts, there were 37 MALES who demonstrated a high prevalence of renal (IV/V lupus nephritis 49%) and a notable incidence of Plaquenil-related retinal toxicity. 62% on HCQ, but 22% D/C HCQ due to retinal toxicity or drug intolerance. https://t.co/FcIFxRoZ6O https://t.co/7OgexLYWge

💡 JAMA Insights: #SleepHealth and #obesity are linked, with insufficient sleep quantity and poor sleep quality associated with weight gain, less healthy diet, and incident obesity. https://t.co/SEj9dwNHiW https://t.co/JbPah4BwDr

QD Clinic: Addressing Severe Gout Flares Dr. Eric Dein, Summit, NJ, discusses a difficult-to-treat case of gout. https://t.co/tochY0BUBj https://t.co/9hQ13cDY9s

Retrospective study, 41 pediatric Behcets Dz pts looked at Inflam. indices (NLR, SII, PIV, CRP/albumin) vs controls. BD systemic involvement in 68%, CNS dz in 10%, Vascular Dz in 12% & major organ dz 46%. Inflamm indices significantly higher in BD w/ systemic, CNS, & Vasc https://t.co/wHiBIaOWWU

Gout & Metabolic Syndrome Dr. John Fitzgerald, Los Angeles, hates the expression "It's only Gout." https://t.co/0JipL3kgcM https://t.co/jszxYAfZwa

Four Decades of Gout Management During this month-long campaign on Gout, we have documented many significant changes in our approach to gout, as well as many unmet needs and deficiencies that merit our continued, primary attention. https://t.co/pTcEtEfQtc https://t.co/yK79xyrEHI

Treatment goals in gout: aim for remission! Rheumatologists are used to the concept of disease remission as this is a treatment goal we use for many chronic rheumatic diseases in our clinical practice. Recently, G-CAN (the Gout and Crystal Arthritis Network), endorsed a https://t.co/PP2NBqvo7E

New Avacopan Analysis Sent to FDA After data manipulation allegations, the FDA has been calling for the vasculitis drug to be pulled from the market since January. Amgen has submitted a third-party review of avacopan's (Tavneos) pivotal trial data and other analyses to the FDA https://t.co/TdLWRMPvnR